Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Military briefing: battle for Sievierodonetsk shows Russian strategy in Donbas
    • Fed officials raised possibility of ‘restrictive’ policy to fight inflation
    • China’s premier issues stark warning on economy as growth stalls
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • Boris Johnson accepts ‘full responsibility’ for partygate
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Pfizer warns of ‘constant waves’ of Covid as complacency grows
    • Fed officials raised possibility of ‘restrictive’ policy to fight inflation
    • Andreessen Horowitz bets on crypto ‘golden era’ with new $4.5bn fund
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • BofA and Citi suspend equity trading with Segantii Capital on block trade concerns
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Pfizer warns of ‘constant waves’ of Covid as complacency grows
    • Elon Musk must find more cash for Twitter deal after scrapping margin loan
    • BofA and Citi suspend equity trading with Segantii Capital on block trade concerns
    • Asset managers divided by HSBC executive’s climate criticism
    • UK government clears £4.25bn Chelsea FC sale to Todd Boehly
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news updates from May 25: Musk must find cash for Twitter deal, Fed officials discussed ‘restrictive’ policy to fight inflation
    • Quant hedge funds reap windfall during 2022 market ructions
    • Wall Street stocks make further gains after release of Fed minutes
    • We’re asking the wrong questions about stablecoins
    • Are consumers . . . just fine?
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Even Sue Gray’s scathing verdict is little threat to this prime minister
    • Olivier Blanchard: ‘There’s a tendency for markets to focus on the present and extrapolate it forever’
    • Boris Johnson should heed warnings from the Australian election
    • Is the ‘subscription economy’ going to feel the Netflix effect?
    • We’re asking the wrong questions about stablecoins
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Vive la différence between work and play
    • Why presenteeism is an enduring corporate narcotic
    • ‘A bonfire of the decencies’: Peter Hennessy on Boris Johnson’s government
    • The cold call is back and worse than ever
    • Welcome to your office in the metaverse
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Kylie Minogue, uncorked
    • The best of Cannes Film Festival 2022
    • The supposed method in El Salvador’s crypto madness
    • The men who stick to a strict style diet
    • I tried remote working from this subtropical island. Don’t get too jealous
  • How to Spend It
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

Bayer AG

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 14 March, 2022
    Russian economy
    Bayer threatens to halt crop supplies to Russia over Ukraine invasion

    Essential products delivered this season but next year in doubt

  • Friday, 15 October, 2021
    Special ReportInnovative Lawyers: Europe
    Amazon’s legal team: ‘We wanted to help’

    Lawyers tackled legal and data privacy issues to deliver Covid test kits in the UK

  • Thursday, 5 August, 2021
    Bayer to buy US start-up Vividion for up to $2bn

    German drugs group to snap up biopharmaceuticals group in innovation push

  • Thursday, 17 June, 2021
    Covid-19 vaccines
    CureVac to press on with mRNA vaccine despite disappointing trials

    German drugmaker believes jab could still be used for some age groups or as booster

  • Thursday, 27 May, 2021
    Bayer to consider ending US retail sales of weedkiller glyphosate

    Chemical group says it wants to reduce risk of litigation after court dismisses $2bn plan to settle cancer claims

  • Wednesday, 10 March, 2021
    Bayer brushes off looming patent expiries

    German group expects new drugs to plug revenue gap as it pledges to increase profits

  • Wednesday, 13 January, 2021
    New Bayer drugs will not bridge revenue gap, says pharma head

    Stefan Oelrich acknowledges challenge of its two bestselling products going off patent

  • Thursday, 7 January, 2021
    Coronavirus treatment
    CureVac teams up with Bayer to accelerate development of Covid vaccine

    Collaboration will help German group deliver several hundred million doses after lagging behind competitors

  • Monday, 26 October, 2020
    LexBiotech
    Bayer/gene therapy: blurred visionary Premium content

    Paying up to $4bn for US-based biotech is unlikely to be transformational

  • Monday, 26 October, 2020
    Bayer spends up to $4bn in gene therapy push

    German group acquires US-based AskBio to strengthen its lucrative pharma business

  • Thursday, 1 October, 2020
    Lex
    Bayer: crop blight Premium content

    It is hard to see what would trigger a near-term turnround in investor sentiment

  • Thursday, 1 October, 2020
    Bayer shares slump on profit warning as pandemic bites deeper

    German group warns coronavirus crisis to hit harder than expected as it writes down assets in agricultural business

  • Friday, 21 August, 2020
    LexPharmaceuticals sector
    Bayer: settling up Premium content

    Unpredictable juries expose potential hazards of German conglomerate’s approach

  • Friday, 26 June, 2020
    News in-depth
    Werner Baumann: Bayer boss takes an expensive step on road to redemption

    German group will spend up to $10.9bn to settle lawsuits over Roundup

  • Thursday, 25 June, 2020
    Lex
    Bayer: tort, a lesson Premium content

    Shareholders would be within their right to agitate for radical change.

  • Wednesday, 24 June, 2020
    Chemicals
    Bayer to pay up to $10.9bn to settle US Roundup lawsuits

    Chief executive of German group says deal will ‘bring a long period of uncertainty to an end’

  • Saturday, 21 March, 2020
    Coronavirus pandemic
    US hospitals panic-buy drugs ahead of coronavirus influx

    Shortages of antimalarials and inhalers feared as purchases spike

  • Wednesday, 11 March, 2020
    European companies
    Investors pursue Deutsche Bank and Bayer boards in US court

    Two shareholders seek damages for directors’ alleged personal responsibility for corporate misconduct

  • Thursday, 27 February, 2020
    Bayer faces more claims over weedkiller cancer allegations

    Rise in plaintiffs comes as German chemicals group reports 19% jump in sales

  • Sunday, 16 February, 2020
    Climate Corp
    Bayer ends digital farming agreement after Twitter backlash

    Farmers voiced concerns on social media over alleged data sharing

  • Wednesday, 30 October, 2019
    Bayer risks mount as US pesticide lawsuits more than double

    German chemicals group faces surge in plaintiffs alleging cancer link to Roundup

  • Thursday, 10 October, 2019
    Bayer sued in Australia over cancer linked to Roundup pesticide

    Farmer’s claims could expand pharma group’s legal woes over Monsanto acquisition

  • Wednesday, 21 August, 2019
    Markets InsightOlaf Storbeck
    Why Germany Inc needs a big governance reboot

    Too many giants of the Dax are suffering from self-inflicted wounds

  • Tuesday, 20 August, 2019
    Bayer agrees $7.6bn sale of animal health business to Elanco

    Deal will create second-biggest player in sector as German chemicals group looks to reorganise

  • Friday, 9 August, 2019
    Bayer boosted by report of $8bn settlement proposal in pesticide legal battle

    German chemicals and pharma group has been under strain amid claims weedkiller causes cancer

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Be part of FT Community

Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

FT LiveTransforming the Agricultural Value ChainNew and collaborative approaches to reducing GHGs
Thursday, 16th Junehttps://transformingagriculture.live.ft.com/agenda
Learn more about FT Community

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In